Core Viewpoint - Chengda Bio (688739) has signed a strategic cooperation agreement with the Institute of Microbiology, Chinese Academy of Sciences, focusing on the prevention of emerging infectious diseases, particularly vector-borne diseases, and aims to jointly apply for national and provincial research projects [1][2]. Group 1: Strategic Cooperation - The agreement emphasizes collaboration in the field of emerging infectious disease prevention, leveraging both parties' resources and expertise to enhance research and development efforts [1]. - Chengda Bio and the Institute of Microbiology will establish a long-term partnership to share resources and amplify their respective strengths in vaccine and biopharmaceutical development [1][2]. Group 2: Research and Development Focus - The collaboration will focus on joint research projects targeting vector-borne disease prevention, with plans to apply for government support and resources to foster innovation [1]. - The strategic partnership aims to accelerate the development of vaccines and biopharmaceuticals for emerging infectious diseases, enriching Chengda Bio's innovation pipeline [2]. Group 3: Intellectual Property and Confidentiality - Each party retains ownership of their respective intellectual property, with jointly developed project outcomes being co-owned as per specific agreements [2]. - Both parties will maintain confidentiality regarding project details and proprietary technologies throughout the collaboration [2].

本次战略合作整合了微生物所病原学研究顶尖资源，与公司现有疫苗研发平台形成协同效应，将加速新 发突发传染病疫苗及生物药研发进程，进一步丰富公司创新管线布局。 格隆汇10月21日丨成大生物(688739.SH)公布，公司与中国科学院微生物研究所(简称"微生物所")于近日 签署《战略合作协议》(简称"本协议")，双方聚焦新发突发传染病领域，重点围绕虫媒传染病预防，联 合申报国家级、省部级科研项目，协同发力应对传染病防控。 ...